<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1979">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05135403</url>
  </required_header>
  <id_info>
    <org_study_id>DHF-00187-01</org_study_id>
    <nct_id>NCT05135403</nct_id>
  </id_info>
  <brief_title>ASSURE WCD Clinical Evaluation - Post Approval Study (ACE-PAS)</brief_title>
  <acronym>ACE-PAS</acronym>
  <official_title>ASSURE WCD Clinical Evaluation - Post Approval Study (ACE-PAS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kestra Medical Technologies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kestra Medical Technologies, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Active surveillance study using real-world data collected in the ASSURE Patient Registry.&#xD;
      Outcome measures are based on analysis of ASSURE Registry data including data recorded by the&#xD;
      WCD then annotated by clinical experts in electrophysiology.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">February 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2024</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Months</target_duration>
  <primary_outcome>
    <measure>Overall shock conversion rate</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Percent of spontaneous episodes of ventricular tachycardia/ventricular fibrillation (VT/VF) successfully converted with one or more shocks ≥ 89.0%</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inappropriate shocks per patient month</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Total inappropriate shocks/cumulative months of WCD use for all patients ≤ 0.0075</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>First shock conversion rate</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Percent of spontaneous episodes of ventricular tachycardia/ventricular fibrillation (VT/VF) converted with a single shock. (report only)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inappropriate shock rate</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Percent of patients who experience at least one inappropriate shock (report only)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Appropriate shock rate per month</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Number of appropriate shocks/cumulative months of WCD use</description>
  </other_outcome>
  <other_outcome>
    <measure>Appropriate shock rate</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Percent of patients who experience at least one appropriate shock</description>
  </other_outcome>
  <other_outcome>
    <measure>Total Shocks delivered</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Number of shocks delivered</description>
  </other_outcome>
  <other_outcome>
    <measure>Shocks diverted</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Number of shocks diverted by patients</description>
  </other_outcome>
  <other_outcome>
    <measure>False positive shock alarm rate</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Number of false positive shock alarms/cumulative WCD use</description>
  </other_outcome>
  <other_outcome>
    <measure>True positive shock alarm rate</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Number of true positive shock alarms/cumulative WCD use</description>
  </other_outcome>
  <other_outcome>
    <measure>Adverse events</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Adverse events related to use of the WCD</description>
  </other_outcome>
  <other_outcome>
    <measure>Average daily device use</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Average daily use of the WCD in hours per day</description>
  </other_outcome>
  <other_outcome>
    <measure>Cumulative device use</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Cumulative device use in days</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">5179</enrollment>
  <condition>Sudden Cardiac Arrest</condition>
  <arm_group>
    <arm_group_label>ASSURE Registry Patients</arm_group_label>
    <description>Patient prescribed the ASSURE WCD who have also consented to participate in the ASSURE Patient Registry. Patients include those with reduced left ventricular ejection fraction (LVEF) and recent myocardial infarction, recent coronary revascularization, or new onset heart failure (HF) to allow for optimization of medical therapy and re-evaluation of cardiac function. Additional indications include ICD explant due to infection, postponed ICD implant, and pending heart transplant.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Defibrillation</intervention_name>
    <description>External defibrillation from a wearable cardioverter defibrillator</description>
    <arm_group_label>ASSURE Registry Patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The ASSURE Wearable Cardioverter Defibrillator (WCD) system is indicated for adult patients&#xD;
        who are at risk or at perceived risk of sudden cardiac arrest (SCA) and are not immediate&#xD;
        candidates for, or refuse, an implantable defibrillator.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patient prescribed the ASSURE wearable cardioverter defibrillator&#xD;
&#xD;
          -  Provided written informed consent to participate in the ASSURE Patient Registry&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who do not meet the Inclusion criteria&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Jeanne Poole, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ron Rowbotham, MSEE, CCRA</last_name>
    <phone>14255264913</phone>
    <email>ron.rowbotham@kestramedical.com</email>
  </overall_contact>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 30, 2021</study_first_submitted>
  <study_first_submitted_qc>November 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 26, 2021</study_first_posted>
  <last_update_submitted>November 24, 2021</last_update_submitted>
  <last_update_submitted_qc>November 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Death, Sudden, Cardiac</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

